BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2025 8:44:58 AM | Browse: 161 | Download: 644
 |
Received |
|
2025-03-25 05:47 |
|
Peer-Review Started |
|
2025-03-25 05:49 |
|
First Decision by Editorial Office Director |
|
2025-04-09 12:50 |
|
Return for Revision |
|
2025-04-09 12:50 |
|
Revised |
|
2025-04-21 20:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-06-09 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-06-09 07:03 |
|
Articles in Press |
|
2025-06-09 07:03 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-26 02:29 |
|
Publish the Manuscript Online |
|
2025-07-22 08:44 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Krzysztof Glaser, Wojciech Glaser, Luca Marino, Marek Ruchala and Federico Bilotta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Krzysztof Glaser, Doctorate Student, Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, Poznan 60-355, Poland. glaser.krzysztof@gmail.com |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Antiobesity medication; Atrial fibrillation; Liraglutide; Semaglutide; Dulaglutide |
| Core Tip |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as potential therapeutic agents in atrial fibrillation (AF) management due to their cardiovascular benefits and weight-reducing effects. While semaglutide has shown promise in reducing AF incidence, liraglutide and dulaglutide have yielded inconsistent results. Compared to sodium-glucose co-transporter 2 inhibitors, which demonstrate more consistent AF reduction, GLP-1 RAs require further investigation to establish their role in AF prevention and management. |
| Publish Date |
2025-07-22 08:44 |
| Citation |
Glaser K, Glaser W, Marino L, Ruchala M, Bilotta F. Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation. World J Cardiol 2025; 17(7): 107510
|
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i7/107510.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i7.107510 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
